Gabapentin Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The gabapentin market encompasses branded and generic formulations of the anticonvulsant drug gabapentin, sold as oral capsules, tablets, and oral solutions for the treatment of epilepsy and neuropathic pain conditions. The market is currently valued at roughly USD 2.46 billion in 2025 and is projected to grow at about 5.44% annually through the next decade. Demand is shaped by clinical prescribing patterns rather than consumer purchasing, since the drug is dispensed primarily through prescription channels.

• •Global market size is approximately USD 2.46 billion in 2025, with a 5.44% CAGR.
• •Indication areas include epilepsy, postherpetic neuralgia, and various off-label pain and psychiatric uses.
• •No official government agency publishes a standalone market valuation for gabapentin, so figures rely on private research providers.

Rising prevalence of neuropathic pain, diabetic neuropathy, and postherpetic neuralgia is the most significant clinical driver of demand. Demographic aging is expanding the patient pool, while growing concern about opioid overuse is pushing clinicians toward gabapentin as a non-opioid alternative for chronic pain. Increased generic competition has also improved affordability and patient access across both developed and emerging markets.

• •Growing burden of diabetes and aging-related nerve pain conditions is increasing prescription volumes.
• •Clinical preference for non-opioid pain management supports wider gabapentin uptake.
• •Generic availability after loss of originator exclusivity has expanded access and stabilized pricing.

The market is commonly segmented by dosage form, with immediate-release oral capsules and tablets dominating volumes and extended-release or once-daily formulations representing a smaller but growing share. By indication, epilepsy and neuropathic pain remain the largest categories, followed by off-label uses in psychiatry and neurology. North America leads global revenue due to high prescription rates and reimbursement coverage, while Europe represents the second-largest region and Asia-Pacific is the fastest-growing as healthcare access expands.

• •Capsules and immediate-release tablets account for the largest share of formulations sold.
• •North America holds the leading regional share, followed by Europe, with Asia-Pacific growing the fastest.
• •Off-label use for anxiety, insomnia, and migraine prevention is a meaningful contributor to overall prescription volume.

What are the recent trends and outlook?

Recent years have seen tighter regulatory scrutiny of gabapentin prescribing due to concerns about misuse, dependence, and respiratory depression when combined with opioids, particularly in the United States. Several U.S. states have reclassified gabapentin as a Schedule V controlled substance or required enhanced prescription monitoring. Despite these restrictions, overall demand is expected to keep growing, supported by new clinical evidence, expanded generic supply, and emerging formulations designed to improve tolerability and dosing convenience.

• •U.S. states are increasingly imposing prescription monitoring or Schedule V controls on gabapentin.
• •Once-daily and extended-release formulations are being developed to improve adherence.
• •Long-term outlook remains positive, with steady mid-single-digit annual growth expected through the early 2030s.